Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) is a biopharmaceutical company focused on therapies for people impacted by kidney disease, and its news flow reflects this specialization. Company announcements frequently highlight progress with Vafseo (vadadustat), a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least three months. Updates include prescribing access among dialysis organizations, clinical trial data such as post-hoc analyses from the INNO2VATE trials, and real-world studies like VOICE and VOCAL that examine mortality, hospitalization, and dosing strategies.
News releases also cover Akebia’s rare kidney disease pipeline, including praliciguat and AKB-097. Investors can follow milestones such as the first patient dosed in a Phase 2 trial of praliciguat for biopsy-confirmed focal segmental glomerulosclerosis (FSGS), plans to evaluate praliciguat in other rare podocytopathies, and the planned Phase 2 basket study of AKB-097 across complement-mediated rare kidney diseases, including IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Additional pipeline updates may involve AKB-9090, a HIF-PH inhibitor entering Phase 1 for acute kidney injury associated with cardiac surgery.
Akebia’s news stream also includes financial results, stock option inducement grants under Nasdaq Listing Rule 5635(c)(4), licensing and supply agreements such as amendments to its Vafseo license with Medice in Europe and certain other countries, and participation in healthcare and investor conferences. For investors tracking AKBA, this news page provides a centralized view of clinical, regulatory, commercial, and corporate developments that shape the company’s kidney disease franchise and pipeline trajectory.
Akebia Therapeutics (Nasdaq: AKBA) will host a virtual R&D Day on April 2, 2026 at 10:00 AM EDT to review its clinical-stage kidney disease pipeline.
Speakers include external scientific experts and management who will discuss praliciguat (Phase 2 FSGS), AKB-097 (Phase 2 planned H2 2026) and AKB-9090 (Phase 1 planned H1 2026), plus a live Q&A and webcast access via the investor website.
Akebia Therapeutics (NASDAQ: AKBA) said its CEO John P. Butler and CFO/Chief Business Officer Erik Ostrowski will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026 at 8:00 AM ET in Miami.
A webcast will be available via the company’s Investors website following the conference. The conference runs March 8-11, 2026.
Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to five newly hired employees on February 27, 2026, totaling 46,200 shares.
The options carry an exercise price of $1.31 (equal to closing price on the grant date), vest over four years (25% after one year, then quarterly), and have a 10-year term under Akebia's inducement award program.
Akebia Therapeutics (Nasdaq: AKBA) reported Q4 2025 net product revenues of $54.3M and full‑year 2025 net product revenues of $227.3M, a 49% increase versus 2024. Vafseo patient access reached 290,000; company expects significant 2026 Vafseo revenue growth. Cash totaled $184.8M, sufficient to fund operations for at least two years. Pipeline progress includes a Phase 2 praliciguat FSGS trial enrolling and a planned 2H 2026 AKB-097 Phase 2 rare kidney disease basket study.
Akebia Therapeutics (Nasdaq: AKBA) will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, before market open. A conference call to discuss results and recent business highlights will be held on Thursday, February 26, 2026 at 8:00 a.m. EST.
Investors must register to receive dial‑in details; a live webcast and an online archive will be available via the Investors section of Akebia's website.
Akebia Therapeutics (Nasdaq: AKBA) said its executive team will take part in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 9:30 AM EST.
A webcast will be available via the company’s Investors site after the conference. The summit runs February 11-12, 2026 in New York City.
Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to two newly hired employees on January 30, 2026, covering an aggregate of 132,675 shares. The options carry a $1.41 exercise price (equal to the closing price on the grant date), vest over four years and have a 10-year term.
The awards were made under Akebia’s inducement award program in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms of the stock option agreements and continued service.
Akebia Therapeutics (Nasdaq: AKBA) provided 2026 corporate updates focused on Vafseo commercial progress and its mid‑stage rare kidney disease pipeline. The company said it has prescribing access covering ~275,000 dialysis patients, completed enrollment in the Phase IV VOICE trial (>2,100 patients) with topline results expected in early 2027, and enrolled ~350 patients in VOCAL with data expected in Q4 2026. Akebia reported Q4 2025 Vafseo net product revenue expectation of $5–$6 million (impacted by a $4.5–$5 million channel inventory reduction) and said revenue growth is expected to resume in Q1 2026. Pipeline updates include first patient dosed in praliciguat Phase 2 for FSGS (Dec 2025) and a planned AKB-097 Phase 2 basket trial starting 2H 2026 with initial data expected in 2027.
Akebia Therapeutics (Nasdaq: AKBA) announced that the first patient has been dosed in a Phase 2 randomized, double-blind, placebo-controlled study of oral once-daily praliciguat for biopsy-confirmed focal segmental glomerulosclerosis (FSGS).
The study will randomize ~60 adults on maximally tolerated ACEi/ARB therapy 1:1 to praliciguat or placebo for a 24-week double-blind period followed by a 24-week open-label extension. The primary endpoint is change in urine protein-to-creatinine ratio (UPCR) at Week 24; a key secondary endpoint is partial remission defined as 40% UPCR reduction and UPCR <1.5 g/g.
Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to a newly hired employee on December 31, 2025 under Nasdaq Listing Rule 5635(c)(4).
The grant covers 197,900 options with an exercise price of $1.61 per share (equal to the closing price on the grant date). Options vest over four years (25% on the first anniversary, then quarterly thereafter), each option has a 10-year term, and awards are subject to Akebia’s inducement award program and a stock option agreement.